Ingo Mellinghoff, MD, FACP: Plenary Presentation, A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Date/Time: Sunday, June 4, 1:05 p.m. CDT

Deb Schrag, MD, MPH: Plenary Presentation, A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048)
Date/Time: Sunday, June 4, 1:41 p.m. CDT

Presenter: Michael Francis Walsh, MD
Session: Clinical Science Symposium, POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition.
Date/Time: Sunday, June 4, 5:06 p.m. CDT

Presenter: Zsofia Kinga Stadler, MD
Session: Redefining early-onset cancer and risk of hereditary cancer predisposition
Date/Time: Sunday, June 4, 4:42 p.m. CDT

Presenter: Alexander Drilon, MD
Session: Poster Discussion Session, A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.
Date/Time: Saturday, June 3, 1:15-2:45 p.m. CDT, On Demand

Presenter: Gregory Riely, MD, PhD
Session: Poster Discussion Session, Efficacy, and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
Date/Time: Sunday, June 4, 4:30-7:00 p.m. CDT

Presenter: Megha Ranganathan, MS, CGC
Session: Case-Based Panel, Managing Cancer Risk in Transgender Patients With Inherited Cancer Predisposition
Date/Time: Sunday, June 4, 11:30 a.m. CDT

Presenter: Fumiko Chino, MD
Session: Oral Abstract Session, Threading the Needle of Patient Access and Provider Well-Being
Date/Time: Saturday, June 3, 2:51 p.m. CDT

Presenter: Alicia Latham, MD, MS
Session: Education Session, Early-Onset Cancer and Genetic Predisposition: Knowns and Unknowns
Date/Time: Saturday, June 3, 1:55 p.m. CDT 

Presenter: Deb Schrag, MD, MPH
Session: Special Sessions, ASCO-ACS Cancer Prevention Award Lecture 
Date/Time: Friday, June 2, 12:00 p.m. (CDT)

Presenter: Mark Andrew Dickson, MD
Session: Case-Based Panel, Navigating Retroperitoneal Sarcoma: Twists, Turns, and Challenges Ahead
Date/Time: Friday, June 2, 4:45 p.m. (CDT)

Presenter: David H. Ilson, MD, PhD
Session: Oral Abstract Session, Is Timing Everything? Immunotherapy in Localized Gastroesophageal Junction and Gastric Cancer
Date/Time: Friday, June 2, 2:45 p.m. (CDT)

Presenter: Alexander Paul Boardman, MD
Session: Rapid Abstract Session, Targeting CD47 in lymphoid malignancies with CAR T cells
Date/Time: Friday, June 2, 4:45 p.m. (CDT)

Presenter: Eileen Mary O’Reilly, MD
Session: Oral Abstract Session, Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial
Date/Time: Friday, June 2, 4:45 p.m. (CDT)

Presenter: Ting Bao, MD, DABMA, MS
Session: Education Session, How to Incorporate Integrative Oncology into Patient Care
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Alicia Latham, MD, MS
Session: Education Session, Early-Onset Cancer and Genetic Predisposition: Knowns and Unknowns
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Dana E. Rathkopf, MD 
Session: Case-Based Panel, PSMA-PET Imaging: Medical Oncology Perspective
Date/Time: Saturday, June 3, 4:45 p.m. (CDT) 

Presenter: Chung-Han Lee, MD, PhD
Session: Poster Session, Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Kelly N. Fitzgerald
Session: Poster Session, Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Maria Isabel Carlo, MD
Session: Poster Session, Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Jonathan Coleman, MD
Session: Poster Session, A phase 3 multicenter study to evaluate the safety and efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in treatment of low-grade (LG) upper tract urothelial cancer (UTUC)
Date/Time: Saturday, June 3, 8:00 a.m. (CDT) 

Presenter: Neeta DSouza
Session: Poster Session, An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC)
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Samuel A Funt, MD
Session: Poster Session, A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT)
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Bob T. Li, MD, PhD, MPH
Session: Poster Session, A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Christopher A. Barker, MD
Session: Poster Session, A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Arielle Elkrief, MD
Session: Poster Session, Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Dazhi Liu
Session: Poster Session, Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Karthigayini Sivaprakasam
Session: Poster Session, ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Matteo Repetto
Session: Poster Session, MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Noura J. Choudhury, MD
Session: Poster Session, Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Edward Christopher Dee
Session: Poster Session, Pan-cancer landscape of FOXA1 alterations: Insights and clinical implications
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Eric Jeffrey Sherman, MD
Session: Poster Session, Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Stephanie Gu
Session: Poster Session, Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Monica F Chen
Session: Poster Session, Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Yelena Y. Janjigian 
Session: Poster Session, TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Darren R. Feldman, MD
Session: Poster Session, First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Lisa Bodei, MD, PhD
Session: Poster Session, FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Gopa Iyer, MD
Session: Poster Session, Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Date/Time: Saturday, June 3, 8:00 a.m. (CDT)

Presenter: Patricia Mae Garcia Santos
Session: Poster Session, Healthcare coverage, access, and affordability among adult immigrant cancer survivors in the United States
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Fumiko Chino, MD
Session: Poster Session, The patient experience of prior authorization for cancer care: Anxiety, delays, and the erosion of trust
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Aaron Philip Mitchell, MD, MPH
Session: Poster Session, Commercial vs. Medicaid insurance and use of high-priced anticancer treatments
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Jenna Bhimani, MBBS, MPH
Session: Poster Session, The evolving landscape of chemotherapy for the treatment of early-stage breast cancer from 2006-2019: Results of a retrospective cohort study
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter:  Aaron Philip Mitchell, MD, MPH
Session: Poster Session, Oncologists’ receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Fumiko Chino, MD
Session: Poster Session, Threading the Needle of Patient Access and Provider Well-Being
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Paul B. Chapman, MD
Session: Poster Session, Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Alexander Noor Shoushtari, MD
Session: Poster Session, The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Paul B. Chapman
Session: Poster Session, Melanomas lacking HLA class I expression and response to checkpoint inhibitor
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Dan Feng
Session: Poster Session, Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Michael Francis Walsh, MD
Session: Poster Session, Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: William D. Tap, MD 
Session: Poster Session, Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: William D. Tap, MD
Session: Poster Session, Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Ciara Marie Kelly, MBBCh BAO
Session: Poster Session, A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Mark Andrew Dickson, MD
Session: Poster Session, SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Sandra P. D’Angelo, MD
Session: Poster Session, A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Justin Jee, MD, PhD
Session: Poster Session, Large-scale clinicogenomic models of solid tumor CNS metastasis
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Lauren Schaff, MD
Session: Poster Session, Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Komal L. Jhaveri, MD, FACP
Session: Poster Session, “Cycling” Toward the FUTURE in Breast Cancer and Beyond
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Alexander E. Drilon, MD
Session: Poster Session, A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)

Presenter: Charles M. Rudin, MD, PhD
Session: Oral Abstract Session, Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC
Date/Time: Saturday, June 3, 3:00 p.m. (CDT)

Presenter: Marjorie Glass Zauderer, MD
Session: Oral Abstract Session, Mesothelioma: Shifting the Odds
Date/Time: Saturday, June 3, 3:00 p.m. (CDT)

Presenter: Chung-Han Lee, MD, PhD
Session: Poster Session, First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study
Date/Time: Saturday, June 3, 3:00 p.m. (CDT)

Presenter: Eileen Mary O’Reilly, MD
Session: Poster Session, AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer
Date/Time: Saturday, June 3, 3:00 p.m. (CDT)

Presenter: Mrinal M. Gounder, MD
Session: Poster Session, RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results
Date/Time: Saturday, June 3, 4:30 p.m. (CDT)

Presenter: Sujana Movva, MD
Session: Poster Session, A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
Date/Time: Saturday, June 3, 4:30 p.m. (CDT)

Presenter: Evan Rosenbaum, MD
Session: Poster Session, Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS)
Date/Time: Saturday, June 3, 4:30 p.m. (CDT)

Presenter: Alicia Latham, MD, MS
Session: Poster Session, Neoplasia detection via colonoscopic surveillance among young patients with MSH6 and PMS2-associated Lynch syndrome
Date/Time: Saturday, June 3, 4:30 p.m. (CDT)

Presenter: Emily Harrold
Session: Poster Session, Clinical and molecular characterization of microsatellite stable (MSS) tumors in patients with Lynch syndrome (LS)
Date/Time: Saturday, June 3, 4:30 p.m. (CDT)

Presenter: James William Smithy
Session: Poster Session, Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT)
Date/Time: Saturday, June 3, 4:30 p.m. (CDT)

Presenter: Neil J. Shah, MBBS
Session: Poster Session, Big data in oncology: Challenges and solutions
Date/Time: Saturday, June 3, 4:30 p.m. (CDT)

Presenter: William P. Tew, MD 
Session: Education Session, Updates on the Status on PARP Inhibitors in Ovarian Cancer 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Alan Loh Ho 
Session: Case-Based Panel, Multidisciplinary Management of Salivary Gland Cancers 
Date/Time: Sunday, June 4, 9:45 a.m. (CDT)  

Presenter: Richard Jirui Lin, MD, PhD 
Session: Education Session, What Is the Role of Allogeneic Stem Cell Transplant for Older Patients With Acute Myeloid Leukemia in 2023? 
Date/Time: Sunday, June 4, 4:30 p.m. (CDT)  

Presenter: Megha Ranganathan, MS, CGC 
Session: Case-Based Panel, Managing Cancer Risk in Transgender Patients With Inherited Cancer Predisposition 
Date/Time: Sunday, June 4, 11:30 a.m. (CDT)  

Presenter: Sarat Chandarlapaty, MD, PhD 
Session: Education Session, The Evolution of ADC Development 
Date/Time: Sunday, June 4, 4:30 p.m. (CDT)  

Presenter: Sara P. Myer 
Session: Poster Session, Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Sara P. Myer 
Session: Poster Session, Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancer 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Natália Polidorio 
Session: Poster Session, Do HER2 low tumors have a distinct clinicopathologic phenotype? 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Sonya Chew 
Session: Poster Session, Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Nour Abuhadra, MD 
Session: Poster Session, Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Bob T. Li, MD, PhD, MPH 
Session: Poster Session, Analytical and clinical validation of Oncomine Dx Target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non–small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02) 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Si-Yang Liu 
Session: Poster Session, Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC) 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Paul K. Paik, MD 
Session: Poster Session, Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Helena Alexandra Yu, MD 
Session: Poster Session, Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Kathryn C. Arbour, MD 
Session: Poster session, Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Dazhi Liu 
Session: Poster Session, Characterization of diverse targetable alterations in ERBB2 and ERBB3 in 93,465 non-small cell lung cancers (NSCLC) 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Rohit Thummalapalli 
Session: Poster Session, Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Arielle Elkrief, MD 
Session: Poster Session, Clinical and genomic landscape of EGFR-mutant lung cancers (LCs) with squamous and adenosquamous differentiation 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Salomon Tendler, MD, PhD 
Session: Poster Session, A theranostic approach: Imaging and therapy of delta-like ligand 3–expressing small cell lung cancers 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Annemarie Shepherd 
Session: Poster Session, Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Joshua Z. Drago 
Session: Poster Session, HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Ezra Rosen, MD, MS 
Session: Poster Session, Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Sherry Shen, MD 
Session: Poster Session, The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction 
Date/Time: Sunday, June 4, 8:00 a.m. (CDT)  

Presenter: Shanu Modi, MD 
Session: Poster Session, Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 
Date/Time: Sunday, June 4, 11:30 a.m. (CDT)  

Presenter: Divya Yerramilli, MD, MBE 
Session: Poster Session, Workplace sexual harassment in academic oncology 
Date/Time: Sunday, June 4, 11:30 a.m. (CDT)  

Presenter: Ghassan K. Abou-Alfa, MD 
Session: Clinical Science Symposium, Is Anti-TIGIT Another Addition to the Hepatocellular Carcinoma Matrix? 
Date/Time: Sunday, June 4, 4:30 p.m. (CDT)  

Presenter: Zsofia Kinga Stadler, MD 
Session: Clinical Science Symposium, Redefining early-onset cancer and risk of hereditary cancer predisposition 
Date/Time: Sunday, June 4, 4:30 p.m. (CDT)  

Presenter: Michael Francis Walsh, MD 
Session: Clinical Science Symposium, POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition 
Date/Time: Sunday, June 4, 4:30 p.m. (CDT)

Presenter: Gregory Riely, MD, PhD
Session: Poster Discussion Session, Efficacy, and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
Date/Time: Sunday, June 4, 4:30-6:00 p.m. CDT

Presenter: Adrienne Ann Boire, MD, PhD
Session: Education Session, Advances in Diagnostics and Response Assessment for Leptomeningeal Disease
Date/Time: Monday, June 5,  11:30 a.m. (CDT)

Presenter: Zsofia Kinga Stadler, MD
Session: Education Session, When Should Tumor Sequencing Prompt A Referral to Cancer Genetics?
Date/Time: Monday, June 5,  8:00 a.m. (CDT)

Presenter: Benjamin Alexander Nacev
Session: Ticketed Session, Integrating Genomic Profiling in the Care of Patients with Sarcoma: From Diagnosis to Therapy
Date/Time: Monday, June 5, 4:00 p.m. (CDT)

Presenter: Fumiko Chino, MD
Session: Education Session, Organizational Strategies to Promote Professional Wellness
Date/Time: Monday, June 5,  9:45 a.m. (CDT)

Presenter: Luis A. Diaz, MD
Session: Case-Based Panel, Medical Oncologist Perspective
Date/Time: Monday, June 5,  4:45 p.m. (CDT)

Presenter: Bianca Santomasso, MD, PhD
Session: Case-Based Panel, Perspective on Incidence and Management of Neurotoxicity
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Danielle Novetsky Friedman, MD
Session: Oral Abstract Session, Clonal hematopoiesis in survivors of childhood cancer.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Janet Alvarez, MD
Session: Poster Session, Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Fiyinfolu Balogun, MD, PhD
Session: Poster Session, Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Sean Judge
Session: Poster Session, The significance of mucin on rectal MRI in patients with locally advanced rectal cancer being considered for watch-and-wait after neoadjuvant therapy.
Date/Time: Monday, June 5, 9:00 a.m. (CDT)

Presenter: Paul Bernard Romesser, MD
Session: Poster Session, Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long course chemoradiation versus short course radiation therapy.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Andrea Cercek, MD
Session: Poster Session, Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Jesse Joshua Smith, MD, PhD, FACS
Session: Poster Session, Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Rona Yaeger, MD
Session: Poster Session, A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Doris M. Ponce, MD, MS
Session: Poster Session, A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Jan Philipp Bewersdorf, MD
Session: Poster Session, A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Gunjan L. Shah, MD
Session: Poster Session, Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Saad Zafar Usmani, MD, MBA, FACP
Session: Poster Session, Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Ross Firestone, MD, PhD
Session: Poster Session, Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Sean Matthew McBride, MD, MPH
Session: Oral Abstract Session, To Protect and Preserve
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Yelena Y. Janjigian, MD
Session: Poster Session, Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Samuel Louis Cytryn, MD
Session: Poster Session, Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Naaz Nasar
Session: Poster Session, Machine learning-based multimodal prediction of prognosis in patients with resected intrahepatic cholangiocarcinoma.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Wungki Park, MD, MS
Session: Poster Session, Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Fergus Keane
Session: Poster Session, Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC).
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Yelena Y. Janjigian, MD
Session: Poster Session, A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.    
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Ghassan K. Abou-Alfa, MD
Session: Poster Session, Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Lorenzo Falchi, MD
Session: Poster Session, Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.
Date/Time: Monday, June 5, 8:00 a.m. (CDT)

Presenter: Michael J. Morris, MD
Session: Education Session, Innovative Solutions to the Challenges of Cancer Clinical Trials: FDA and NCI perspectives
Date/Time: Monday, June 5, 11:30 a.m. (CDT) 

Presenter: Jessica Scott, PhD
Session: Case-Based Panel, Cardiac Toxicity in Oncology: Prevention and Surveillance Strategies for Early and Late Effects of Treatment: The Exercise Physiologist Perspective
Date/Time: Monday, June 5, 11:30 a.m. (CDT)  

Presenter: Sujana Movva, MD
Session: Oral Abstract Session, Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort
Date/Time: Monday, June 5, 11:30 a.m. (CDT) 

Presenter: Robert J. Motzer, MD
Session: Oral Abstract Session, Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial
Date/Time: Monday, June 5, 11:30 a.m. (CDT) 

Presenter: Helen Ajufo, MD
Session: Poster Discussion Session, Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial
Date/Time: Monday, June 5, 11:30 a.m. (CDT) 

Presenter: Floris S. Verheij
Session: Poster Discussion Session, Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial
Date/Time: Monday, June 5, 1:15 p.m. (CDT) 

Presenter: Ryan M. Kahn, MD, MHS
Session: Poster Session, Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Ying L Liu, MD, MPH
Session: Poster Session, Pathogenic germline variants in patients with endometrial cancer across diverse ancestries
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Antoine Desilets
Session: Poster Session, A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Maliheh Mohamadpour, MD
Session: Poster Session, A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Alan Loh Ho, MD, PhD
Session: Poster Session, A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Brian H. Kushner, MD
Session: Poster Session, Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Neeta Pandit-Taskar, MD
Session: Poster Session, 8F-MFBG PET imaging in patients with neuroblastoma: Lesion targeting and comparison with MIBG
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Lorenzo Falchi, MD
Session: Poster Session, Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Erin Mary Bange, MD, MSCE
Session: Poster Session, Are we ready to mitigate time toxicity of cancer care? Oncologists’ perceptions on digital interventions to fast-track cancer care
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Semanti Mukherjee
Session: Poster Session, Association of smoking history extracted from electronic health records (EHR) using machine-learning methods and tumor characteristics in patients with lung cancer
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Sarah P. Suehnholz, PhD
Session: Poster Session, Quantifying the growth of clinical actionability in precision oncology using OncoKB
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Robert Michael Daly, MD, MBA
Session: Poster Session, Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Victoria Susana Blinder, MD
Session: Poster Session, Patient-reported usefulness of an intervention to promote job retention among women undergoing (neo)adjuvant breast cancer chemotherapy
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Fumiko Chino, MD
Session: Poster Session, “It was so many hoops to jump through”: Patient-reported administrative burden from disability, Family and Medical Leave Act (FMLA), and insurance appeals
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Samyukta Mullangi, MD, MBDA
Session: Poster Session, Association of participation in Medicare’s Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysis
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Iris Zhi, MD, PhD
Session: Poster Session, Association of participation in Medicare’s Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysis
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Sherry Shen, MD
Session: Poster Session, Evaluation of a mobile behavior change program for weight loss in breast cancer survivors: A prospective single-arm pilot study
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Kirin Saint
Session: Poster Session, Impact of exercise on chemotherapy-induced peripheral neuropathy (CIPN) in survivors with post-treatment primary breast cancer
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Anthony Francis Yu, MD, MS
Session: Poster Session, Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Jun J. Mao, MD, MSCE
Session: Poster Session, Acupuncture versus massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Shari Beth Goldfarb, MD
Session: Poster Session, Efficacy of paxman scalp cooling system at lower temperatures for prevention of anthracycline associated chemotherapy induced alopecia
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Talya Salz, PhD
Session: Poster Session, Experiences with pain management for survivors of complex cancers: Focus on opioids and cannabis
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Kirin Saint
Session: Poster Session, A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Ivana Lopez-Nieves
Session: Poster Session, A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy in survivors of cancer
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Jamie S. Ostroff, PhD
Session: Poster Session, Empathic communication skills training: Randomized controlled trial to reduce lung cancer stigma in lung cancer care
Date/Time: Monday, June 5, 1:15 p.m. (CDT)

Presenter: Vijai Joseph, PhD
Session: Oral Abstract Session, Ancestry-adjusted genomic analysis to identify known and novel associations with single and multiple cancer phenotypes
Date/Time: Monday, June 5, 3:00 p.m. (CDT)

Presenter: Saad Zafar Usmani, MD, MBA, FACP
Session: Poster Session, A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9
Date/Time: Monday, June 5, 3:00 p.m. (CDT)

Presenter: Lara Dunn, MD
Session: Poster Session, Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)
Date/Time: Monday, June 5, 4:00 p.m. (CDT) 

Presenter: Martinique Ogle
Session: Poster Session, Fertility post immune checkpoint blockade
Date/Time: Monday, June 5, 4:30 p.m. (CDT) 

Presenter: Shari Beth Goldfarb, MD
Session: Poster Session, Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy
Date/Time: Monday, June 5, 4:30 p.m. (CDT) 

Presenter: Alexander E. Drilon
Session: Highlights of the Day Session, Highlights of Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date/Time: Tuesday, June 6, 8:00 a.m. (CDT)